Sarcoidosis – Epidemiology – Mature Markets Data

DRG Epidemiology’s coverage of sarcoidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of sarcoidosis for each country, as well as annualized case counts projected to the national population. The patient populations are forecast over a period of 20 years.

DRG Epidemiology’s sarcoidosis forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of sarcoidosis over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following sarcoidosis subpopulations:

  • Diagnosed incident cases.
  • Diagnosed lifetime prevalent cases.
  • Diagnosed current prevalent cases.
  • Organ involvement in sarcoidosis.

Note: Coverage may vary by country.

Table of contents

  • Sarcoidosis - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Key Updates
      • Incidence of Sarcoidosis per 100,000 per Year Among People Aged 20+ in 2021 and 2041
      • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Sarcoidosis over the Next 20 Years
      • Number of Incident Cases of Sarcoidosis Avoided in 2041 in the Countries Under Study due to Trends in Risk or Survival
      • Number of Incident Cases of Sarcoidosis Avoided in 2041 in the Countries Under Study due to Trends in Risk or Survival
    • Epidemiology Data
    • Methods
      • Diagnosed Incidence
      • Diagnosed Lifetime Prevalence
      • Diagnosed Current Prevalence
      • Organ Involvement in Sarcoidosis
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Sarcoidosis
        • Studies Excluded From the Analysis of Sarcoidosis
      • Risk/Protective Factors
        • Risk/Protective Factors for Sarcoidosis
      • Bibliography
      • Abbreviation Table
      • Glossary

Login to access report